Missed Dr Adam Clauss in Malta? SENISCA will be represented at the upcoming Science of Skincare Summit in Austin, Texas.
SENISCA
Biotechnology
Exeter, Devon 1,338 followers
Applying world-leading molecular genetics to solve the diseases and aesthetic signs of ageing
About us
SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics). Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence. This innovation works by restoring the ability of cells to ‘fine tune’ the expression of their genes to rejuvenate aged cells. At SENISCA, we are using this knowledge, concerning how and why cells become senescent, to develop a new generation of oligonucleotide-based interventions, to turn back the ageing clock in old cells and to target the diseases and aesthetic signs of ageing.
- Website
-
http://www.senisca.com
External link for SENISCA
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Exeter, Devon
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
Get directions
RILD Building
Barrack Road
Exeter, Devon EX25DW, GB
Employees at SENISCA
Updates
-
Great work Adam! Even picking up an award on the road 🏆
🏆 SENISCA’s Small Molecule Reduces Senescence in Aged Cells – Best Short Oral at Skin Challenges 2024! Adam Clauss from SENISCA won the Best Short Oral Presentation Award at Skin Ageing & Challenges 2024. Dr. Clauss's research reveals small molecules that reverse senescence in skin cells without affecting cell proliferation. These molecules show similar effects to dasatinib and quercetin, offering exciting new possibilities for skin rejuvenation. Skin Challenges team congratulates Dr. Clauss. Well done👏! 🔗: https://lnkd.in/dgCUAg7y #SkinAging #AntiAging #CellularSenescence #SkinHealth #SkinChallenges2024
-
-
SENISCA reposted this
Targeting Cellular Aging: A Significant Advance in Combating Senescence! Adam Clauss from SENISCA, United Kingdom, shared his latest findings at #SkinAgeing2024. His research sheds light on an innovative intervention that targets a new hallmark of ageing to effectively reduce senescence in aged primary cells. By modulating splicing factor expression, Dr. Clauss and his team have identified small molecule compounds that reverse cellular ageing effects in human primary dermal fibroblasts. Notably, these compounds reduce senescent cell load and DNA damage without impacting cell proliferation, with some results comparable to those of dasatinib and quercetin (DQ). This novel approach paves the way for cosmeceutical solutions aimed at addressing the root causes of cellular ageing. #SkinAgeingAndChallenges #skin #aging #cellularsenescence #antiaging #cosmeceuticals #dermatology #innovation
-
-
SENISCA reposted this
Innovation leadership | Portfolio management | Drug Discovery & Development | Advanced Therapies
I am representing SENISCA today at the Skin Ageing and Challenges meeting in Malta. I am excited to tell you more about how we at #senisca can reprogram senescent cells in the skin.
-
-
Can we reverse skin cell ageing? It starts with our world-leading expertise on skin and how it changes throughout age... Meet our skin therapeutics lead, Dr Adam Clauss, to find out more about how we are addressing these challenges. He will be at the 15th International Conference for 'Skin Ageing and Challenges' tomorrow and wednesday.
15th International Conference - Skin Ageing & Challenges - Skin Aging & Challenges 2024
https://skin-challenges.com
-
Interested in our approach to skin rejuvenation? Come meet our VP Dermatology - Adam Clauss He is at the Biofilms Research Center for Biointerfaces Annual Workshop 2024 today and tomorrow at Malmö University and happy to talk about all things skin and SENISCA.
-
-
Our CEO, Sarah Cole, will be presenting! Come chat to Sarah to find out more about SENISCA and our award-winning therapeutic approaches.
We’re excited to announce we are hosting a Regional Innovation for the Modern Economy: South West Health & Life Sciences Summit in Bristol, next week! 👏 This exclusive event will bring together leading minds from government, academia, and industry to explore how we can accelerate groundbreaking health and life sciences innovation in the region. We are excited to hear from speakers like Sir Patrick Vallance, Darren Jones MP, Sir Richard L. Olver FREng, Michele Barbour and many more 🗣️ Thanks to our fantastic partners at QantX, British Business Bank, University of Bristol, Bristol Innovations, SETsquared Partnership, Barclays Eagle Labs & Evelyn Partners for supporting the Summit, we can't wait to hear from these brilliant speakers 💙 #Innovation #HealthTech #LifeSciences
-
-
Welcome Dr Alice Ghidini! Meet our new VP of Oligotherapeutics Development She has over 13 years of experience in RNA therapeutics, having trained in the labs of leading pioneers of the field (Karolinska, ETH, and Caltech). Alice continued her focus on RNA-based drug development in both pharmaceutical (AstraZeneca) and biotech settings (Sixfold Bioscience), where she was awarded a UKRI Future Leaders Fellowship for her work in oligonucleotide delivery design. Super excited for SENISCA to be guided forward with your expertise.
-
-
SENISCA won! Commercialisation project of the year - University of Exeter Knowledge Exchange Awards Thanks so much to the University, the Exeter Innovation team, all the sponsors and of course the judges. Super proud to be given this award and to wave the green UOE flag. #bleedgreen #winners #rnabiology #senescence #commercialisation #ExeKEAwards24
-
Interested in SENISCAs approach to age-related diseases? Meet our CDO Tim Sebastian Schmidt He'll be at the 3rd Annual Inhaled and Nasal Biologics/DNA forum in Cambridge later this week. Come chat about our progress in developing novel inhaled senomorphic oligonucleotides.
Inhaled & Nasal Biologics | DNA Forum 2024
intertek.com